RECENT NEWS
Bloomberg  Jul 1 
(Update1) Medicare, the U.S. health-insurance program for elderly and disabled people, proposed fee changes designed to increase payments to family doctors, general practitioners and others who give primary care.
New York Times  Jun 27 
Mr. Derzon was an early proponent of universal health care coverage.
Bloomberg  Jun 24 
Senate legislation to overhaul the U.S. health-care system will likely drop a proposed mandate that all employers offer medical benefits to their workers or pay a penalty, a senior Democratic lawmaker said. The move may make it easier to reach a...
FiercePharma  Jun 23 
Fifteen U.S. states are crying foul over Wyeth's Protonix pricing. The states filed a federal complaint alleging that the drugmaker avoided millions of dollars in rebates to Medicaid programs that had bought the acid-reducing drug. The complaint...
StreetInsider.com  Jun 19 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Aetna+%28AET%29+Wins+Contracts+for+Central%2C+Eastern+and+Western+Missouri+Medicaid/4743708.html for the full story.
New York Times  Jun 16 
A senator calls for greater protections for purchasers of long-term care insurance policies.
Wall Street Journal  Jun 5 
Magellan Health Services announced plans to pay $110 million for Coventry Health Care's Medicaid-administration business, First Health Services.
Wall Street Journal  May 28 
Sanofi-Aventis agreed to pay $95.5 million to settle a Medicaid "best price" dispute over nasal sprays, without admitting wrongdoing.
Motley Fool  May 19 
Pfizer may inherit a lawsuit.
FiercePharma  May 19 
Two whistleblower suits against Wyeth just gained some heavyweight clout. The U.S. Justice Department and 16 states have joined the lawsuits, which accuse Wyeth of defrauding the government by discounting Protonix for hospitals without offering...
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
BULLS: REASONS TO BUY
Bulls: Reasons To Buy
Feeling Bullish? Be the first to explain why this would make a good investment
See All (0)
BEARS: REASONS TO SELL
Bears: Reasons To Sell
Feeling Bearish? Be the first to explain why this would make a poor investment
See All (0)
 
TOP CONTRIBUTORS

Medicaid is the U.S. health care program for people with limited resources, and it serves low income parents, children, people with disabilities, and low income seniors. It is jointly funded by the states and the federal government and managed by the states. Medicaid is distinctly different from Medicare, which is an entitlement program funded entirely at the federal level and provides health insurance to people aged 65 and older. Medicaid is not an entitlement program, but is instead a needs-based social welfare program in which eligibility is determined by income. It covers a wider range of health services than Medicare and is funded by states as well as the federal government. It is possible to be eligible for both Medicaid and Medicare, and several million Americans are enrolled in both programs.

The Pharmaceutical Industry depends on Medicare and Medicaid funding for a significant percentage of its revenues. Of the two, however, Medicare's impact on the business of Health Care in America is much greater. The senior citizens of all income levels served by Medicare make up the major target population for most of the pharma industry's drugs. This is not the case for the low income, younger patients enrolled in Medicaid. Certain drugs and treatments, however, do have their revenues tied closely to Medicaid spending - notably HIV and AIDS, where more than half of people living with AIDS are estimated to receive Medicaid payments.

 
Worried about pump and dump?
We review changes
for stock spam
Want to make Wikinvest better?
We need your help,
contribute today
Do you write software?
We are recruiting
the best engineers
Like Wikinvest?
Spread the word —
Tell your friends!
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki